close icon

Walgreens Stock Dips Below $45 as KKR Deal Stalls

We last wrote about Walgreens stock on November 11th, 2019. Shares were hovering around $62 after news that KKR’s was willing to take the company private. It was going to be the largest leveraged buyout in history.

We, on the other hand, were more interested in what was going to happen with the stock in the absence of a deal. So, we turned to Elliott Wave analysis in our search for an answer. The chart below, published almost four months ago, shows that KKR really was the bulls’ final hope.

Walgreens stock ready to fall if KKR deal collapses

Walgreens’ 4-hour chart revealed a textbook 5-3 wave cycle. There was a five-wave impulse between $86.31 and $49.03, followed by a simple a-b-c zigzag up to $64.50. This pattern meant that unless KKR managed to complete the takeover, pure market forces were going to drag WBA below $50 again.

Unfortunately for the bulls, it soon became evident that financing the deal would be problematic even for KKR. The market quickly lost confidence and Walgreens stock started sliding again.

Walgreens stock dips below $45 as KKR deal seems unlikely

The price fell to $44.61 last week, down 28% since November 11th. In that case, an Elliott Wave pattern proved more reliable than the third biggest private equity company in the world.

Similar Elliott Wave setups occur in the Forex, crypto and commodity markets, as well. Our Elliott Wave Video Course can teach you how to uncover them yourself!



Stay informed with our newsletter

Latest Elliott Wave analysis on different topics delivered to you weekly.

Privacy policy
You may also like:

AMN Healthcare Stock to Suffer a 2020-Like Drop

AMN Healthcare Services provides workforce and staffing solutions to healthcare facilities in the U.S. The company is relatively small with a market capitalization of less than $4 billion. However, small companies can make for excellent returns if one happens to identify the winners. And indeed, between late-2011 and early-2020, AMN stock from under $4 to…

Read More »

Zoetis Stock Getting Ahead of Itself, Invites Correction

Based in Parsippany, NJ, Zoetis Inc. is an animal medicine and vaccine developer and manufacturer. The company went public in 2013 and has been enjoying steady growth since. With the stock currently above $160 a share, Zoetis holds a market cap of nearly $80 billion. For a profitable and growing company like Zoetis, a rising…

Read More »

CBOE Stock Looking Good After a Record Year

CBOE Global Markets Inc. is an equities, options and futures exchange operator in the U.S. and Europe. The company traces its roots back to Chicago in 1973, when it practically invented options trading in its present form. CBOE is literally part of the very infrastructure of modern financial markets. So it is not surprising that…

Read More »

Novo Nordisk Bulls Have an Elliott Wave Problem

Novo Nordisk A/S is a Danish pharmaceuticals major with a market cap of over $160 billion. People need their medication even in recessions, so the company’s business wasn’t as affected by the 2020 crisis as most other industries. Novo Nordisk remains a top-notch pharma with consistent profits and revenue and no debt whatsoever. And the…

Read More »

Lockheed ‘s Correction Still Unfolding as Expected

Almost a year and a half ago, in July 2019, we wrote that Lockheed Martin is likely “setting the stage for an unpleasant surprise.” The stock had just reached a new all-time high and was trading at $370 a share. Optimism was in the air and analysts were more bullish than ever. An indeed, fundamentally,…

Read More »

Campari Bulls to Get a Serious Hangover Soon

Campari is an Italian liquor and spirits maker with traditions dating back to 1860. The company’s stock price plunged sharply in March along with the markets in general and then recovered just as quickly to new records by year-end. As shares hover near all-time highs, however, dark clouds appear to be gathering over the spirits…

Read More »

Experian to Drop 35% Before Uptrend Can Resume

Like most technology firms, Experian adapted to the new work-from-home environment relatively quickly. The Irish data and analytics company even managed to grow its revenue in 2020, even though its EPS didn’t change much from 2019. After the initial coronavirus selloff in March, the stock swiftly recovered, as well. EXPN.L is currently hovering around 2900…

Read More »

More analyses